



Ref: CTO 2016 055 [1]

Invertebrates: *Hymenolepis diminuta* for human use

CTO direction to biosecurity inspectors for the clearance of *Hymenolepis diminuta* (rat tapeworm) for human use

Pursuant to section 27(1)(d)(iii) of the Biosecurity Act 1993 I, Lucy Johnston, Manager Animal Imports, Ministry for Primary Industries (under delegated authority), give the following directions for *Hymenolepis diminuta* (rat tapeworm), shipped from Biome Restoration Ltd in England, to be given clearance in accordance with the following measures, different from those in the applicable import health standard for the importation of invertebrates into New Zealand (INVNONIC.ALL):

Clauses 11.1 and 11.2

Clauses 11.1 and 11.2 of INVNONIC.ALL state:

- 11.1 Following biosecurity authorisation being given, the container must proceed to the approved registered transitional facility which must be operated according to the MAF Standard 154.02.08: Transitional and containment facility for invertebrates.
- 11.2 On arrival in the transitional facility the culture must be subjected to such disease testing, identity confirmation, treatments or procedures as required by the permit to import, the MAF Standard 154.02.08 and the Animal Imports/Exports Group Manager.

The *Hymenolepis diminuta* shipped from Biome Restoration Ltd (England) for human use does not need to be imported into a transitional facility approved to, and operating under, 154.02.18 (Transitional and Containment Facilities for Invertebrates) if the importation of the product is accompanied by validated import permit as well as a signed and dated manufacturer's declaration that verifies the following:

- a) *H. diminuta* are laboratory raised; and
- b) *H. diminuta* are for human use only; and
- c) the species being sent to New Zealand have been identified as *H. diminuta* (rat tapeworm) and not another species.

The reason for directing clearance is that the biosecurity risks associated with this CTO direction have been assessed and are managed effectively. Advice was received from MedSafe (Ministry of Health) which requires the distribution of *H. diminuta* to be in compliance with the requirements of the Medicines Act 1981 if intended to be administered to a person for a therapeutic purpose.

This direction takes effect from the date of signing and continues in effect until amended or revoked.